Publication
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Journal Paper/Review - Feb 16, 2023
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
Jörger, Markus
chief of serviceMedizinische Onkologie und Hämatologie · Dept. I
175
43
Hundsberger, Thomas
chief of serviceNeurologie, Medizinische Onkologie und Hämatologie · Dept. III, Dept. I
113
12
Haefliger, Simon
2
0
von Moos, Roger
58
1
Hottinger, Andreas F
8
0
Kaindl, Thomas
2
0
Engelhardt, Marc
2
0
Marszewska, Michalina
1
0
Lane, Heidi
2
0
Roth, Patrick
16
0
Stathis, Anastasios
8
0